TheraRadar
← Back
Data updated: Mar 29, 2026

SINOTHERAPEUTICS INC

ImmunologyGastroenterologyCardiovascular
Generics

SINOTHERAPEUTICS INC is a generic drug manufacturer focused on Immunology, Gastroenterology, Cardiovascular.

2017
Since
7
Drugs
-
Trials
149
Approved (2yr)

Key Drugs

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
metformin hydrochloride, sitagliptin
· 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 2025-12-02
TOFACITINIB CITRATE 2025-11-17
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 70%
1 drugs Phase 3: 5 Phase 2: 3
Gastroenterology 13%
1 drugs
Cardiovascular 13%
1 drugs
Dermatology 4%
0 drugs Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

BAUSCH specialty
Dermatology, Immunology, Cardiovascular, Gastroenterology
Pfizer big-pharma
Dermatology, Immunology, Gastroenterology
COREPHARMA other
Cardiovascular, Immunology, Gastroenterology, Dermatology
COSETTE other
Cardiovascular, Dermatology, Immunology
BAUSCH AND LOMB specialty
Cardiovascular, Dermatology, Immunology